Currently, a study by Park et al. [10] assessing the effects of novel anti-VCAM-1 antibodies in hypercholesterolemic mouse models remains the most comprehensive investigation of the therapeutic potential of VCAM-1 antibodies for treating atherosclerosis. Here, VCAM1 is linked to atherosclerosis.